<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455154</url>
  </required_header>
  <id_info>
    <org_study_id>RJBC1502</org_study_id>
    <nct_id>NCT02455154</nct_id>
  </id_info>
  <brief_title>Traditional Chinese Medicine as Preventive Method for Osteoporosis Induced by Adjuvant Endocrine Therapy</brief_title>
  <acronym>COAT</acronym>
  <official_title>Traditional Chinese Medicine as Preventive Method for Osteoporosis in Early Breast Cancer Patients Receiving Adjuvant Endocrine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the efficacy of two Traditional Chinese Medicine in preventing osteoporosis in
      patients receiving adjuvant endocrine therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the most common malignant tumor in female wolrdwide. Results from clinical
      trials like ATAC trial have demonstrated the efficacy of AIs in postmenopausal breast cancer
      patients. Meanwhile it may cause a certain rate of osteoporosis in postmenopausal patients.
      The aim of this trial is to test the efficacy of two traditional Chinese medicine in
      preventing osteoporosis in patients receiving adjuvant endocrine therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Bone Mineral Density</measure>
    <time_frame>1 year</time_frame>
    <description>The change of bone mineral density of the L2-L4 region of the spine and hip between pre- and post-endocrine therapy for one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Frature Rate</measure>
    <time_frame>1 year</time_frame>
    <description>the rate of bone fracture in patient receiving endocrine therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Metabolism</measure>
    <time_frame>1 year</time_frame>
    <description>The change of bone metabolism assessed by the scale of serum bone alkaline phosphatase, serum C-telopeptide and urineN-telopeptide between pre- and post-endocrine therapy for one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>the rate of patients without disease</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Early Breast Cancer patients receiving adjuvant endocrine therapy
Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole + Xinglinggubao</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early Breast Cancer patients receiving adjuvant endocrine therapy plus Xianlinggubao
Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.
Xinglinggubao: 0.5g bid po</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole + Zhongyaofufang</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early Breast Cancer patients receiving adjuvant endocrine therapyplus Zhongyaofufang (Traditional Chinses Medicine)
Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.
Zhongyaofufang: qow po</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole endocrine therapy for 2.5mg qd po.</description>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_label>Letrozole + Xinglinggubao</arm_group_label>
    <arm_group_label>Letrozole + Zhongyaofufang</arm_group_label>
    <other_name>L</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zhongyaofufang</intervention_name>
    <description>Traditional Chinese Medicine for patients with Osteoporosis</description>
    <arm_group_label>Letrozole + Zhongyaofufang</arm_group_label>
    <other_name>Z</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xianlinggubao</intervention_name>
    <description>Traditional Chinese Medicine for patients with Osteoporosis</description>
    <arm_group_label>Letrozole + Xinglinggubao</arm_group_label>
    <other_name>X</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed invasive breast cancer;

          -  Post-surgery, primary lesion been removed;

          -  Post-Menopausal patients or pre-menopausal patients who will receive ovarian function
             suppression;

          -  Histologically confirmed ER and/or PR positive ;

          -  Receiving adjuvant AIs therapy in the following one years;

          -  Leukocyte ≥ 3*10(9)/L; Platelets ≥ 75*10(9)/L;

          -  Serum glutamate oxaloacetate(AST/SGOT) or serum glutamic-pyruvic
             transaminase(ALT/SGPT) &lt;2.5 times of upper limit of normal range;

          -  Serum creatinine/blood urea nitrogen(BUN) ≤ upper limit of normal (UNL) range;

          -  Written informed consent according to the local ethics committee equirements;

        Exclusion Criteria:

          -  Metastatic Breast Cancer;

          -  Received Neo-Adjuvant Endocrine Therapy;

          -  History of pelvic fracture or bone metabolic disease;

          -  Received drugs interfering bone metabolism in the last 12 months;

          -  Baseline Bone Mineral Density: T &lt; -2SD;

          -  With other primary malignant disease;

          -  With severe non-malignant co-morbidity that will influence long-term follow up;

          -  Known severe hypersensitivity to any drugs in this study;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunwei Shen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weiqi Gao, MD</last_name>
    <phone>0086-13641811209</phone>
    <email>gaoweiqi2733@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaosong Chen, PHD</last_name>
    <phone>00862164370045</phone>
    <phone_ext>602268</phone_ext>
    <email>chenxiaosong0156@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiqi Gao, MD</last_name>
      <phone>0086-13641811209</phone>
      <email>gaoweiqi2733@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaosong Chen, PHD</last_name>
      <phone>00862164370045</phone>
      <phone_ext>602268</phone_ext>
      <email>chenxiaosong0156@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kunwei Shen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kunwei Shen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Chinese Traditional Medicine</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>adjuvant endocrine therapy</keyword>
  <keyword>early breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

